Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Two years ago, as Iveric Bio went through late-stage studies of its main experimental drug, it began attracting interest from potential buyers. Five companies ended …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look